NCT06782971 Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX
| NCT ID | NCT06782971 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Clinical Hub for Interventional Research (CHOIR) |
| Condition | AML - Acute Myeloid Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 25 participants |
| Start Date | 2025-06-06 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25 participants in total. It began in 2025-06-06 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to develop new ways to test new drug combinations to kill tumour cells, in patients with acute myeloid leukemia (AML). The main questions it aims to answer are: * Are there new ways to speed up discovery of better treatments for AML patients using AML cells from individual from patients in special mice that can accept human tissue? * Do these mice show treatment responses that are similar to the individual AML patient from whom cells were derived? Participants with AML who are taking standard of care treatment of venetoclax and azacitidine will be asked to donate blood and bone marrow samples for this study.
Eligibility Criteria
Inclusion Criteria: 1. Age 18 years and above 2. Patients with suspicion of AML requiring screening procedures 3. Documented diagnosis of AML by WHO Classification and/or International Consensus Classification. * Regardless of the number and type of prior lines of therapy or eligibility for allogeneic stem cell transplantation. * All AML subtypes are eligible. * Concurrent participation in clinical trials is allowed. 4. Documented myeloblast percentage ≥20% in the bone marrow or peripheral blood within 12 weeks of C1D1 confirmed by bone marrow aspirate or peripheral blood smear. 5. Planned to commence venetoclax and azacitidine therapy. 6. Provision of written informed consent prior to any study-related assessments or procedures being carried out. Exclusion Criteria: 1\. Presence of any condition that, by assessment of the Investigator, would compromise the safety of the patient if they participated, the quality of trial data, or their adherence to the study-specified procedures.
Contact & Investigator
John Pimanda, Professor
PRINCIPAL INVESTIGATOR
University of New South Wales
Frequently Asked Questions
Who can join the NCT06782971 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying AML - Acute Myeloid Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06782971 currently recruiting?
Yes, NCT06782971 is actively recruiting participants. Contact the research team at cosmos.jcsmr@anu.edu.au for enrollment information.
Where is the NCT06782971 trial being conducted?
This trial is being conducted at Canberra, Australia, Sydney, Australia, Sydney, Australia, Westmead, Australia.
Who is sponsoring the NCT06782971 clinical trial?
NCT06782971 is sponsored by Clinical Hub for Interventional Research (CHOIR). The principal investigator is John Pimanda, Professor at University of New South Wales. The trial plans to enroll 25 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.